A Phase 1-2, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Once-Daily Administration of HS10296 in Patients with Locally Advanced or Metastatic Non- Small-Cell Lung Cancer Who Have Progressed Follow

Project: Research project

Project Details

StatusFinished
Effective start/end date5/27/17 → 5/26/19

Funding

  • Hansoh Pharmaceutical Group Company, LTD ( Award # ): $13,625.00